Cure8 research brief
The review aggregates published instances where combining two advanced immunomodulators was followed by improvement in pyoderma gangrenosum, a serious skin complication often seen in people with IBD. However, the evidence is uncontrolled and incomplete, so it doesn't prove DTT works or is safe for PG.
Clinicians treating refractory PG, multidisciplinary IBD care teams (gastroenterology + dermatology), researchers on DTT strategies, and patients with IBD and severe skin involvement.
This paper reviewed 14 reports covering 17 PG treatment exposures; 14 had extractable skin outcomes (all reported as improved or resolved) and most exposures were in patients with IBD.
Reporting was incomplete for regimen details, diagnostic methods, follow-up and safety, so these observations do not prove that DTT is effective or safer than other approaches.
The authors recommend building a prospective dermatology-embedded registry within IBD DTT programmes to standardise PG diagnosis, lesion documentation, co-intervention recording and safety monitoring before treating PG with DTT becomes routine.
This record is an abstract-level systematic review summarising uncontrolled case reports and series; it emphasises the need for prospective registries with standardised outcome and safety reporting before DTT is adopted more widely for PG.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of Interest: Mohammed Shanshal and George Karanasios declare no conflicts of interest relevant to this work. Ethical Approval: Ethical approval was not required because this review used only data from published reports and did not involve new patient recruitment, direct participant involvement or unpublished identifiable patient data.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
